- In April 2025, MetaSystems Probes announced the expansion of its IVDR-certified XCyting FISH probes to 23 countries across Europe and beyond. This aims to increase market reach for prenatal aneusomy testing and other applications, demonstrating a commitment to regulatory compliance and broader accessibility of FISH diagnostics
- In October 2023, Monte Rosa Therapeutics, a clinical-stage biotechnology company specializing in molecular glue degraders (MGDs), entered into a strategic partnership and licensing agreement with F. Hoffmann-La Roche AG. This collaboration focuses on the discovery and development of novel MGDs to treat cancer and neurological disorders
- In July 2023, KromaTiD, a company focused on single-cell analysis tools for cell and gene therapy, announced the release of over 300 new centromere, telomere, and gene probes. These probes are designed for use in their directional Genomic Hybridization (dGH) in-Site assays, which are crucial for assessing genomic structural variation and gene-editing outcomes
- In March 2023, KromaTiD launched the dGH in-Site CAR-T Kit, a tool for single-cell gene editing analysis for TRAC & B2M in the cell and gene therapy market. This innovation is designed to enhance precision in CAR-T therapy research, providing advanced tools for researchers and developers
- In March 2023, Sysmex Corporation introduced the first IVDR-compliant DNA FISH probes to the market, designed by scientists for direct in-situ detection of genetic changes across various sample types. These ready-to-use, premixed, and directly labeled probes are intended to ensure batch-to-batch consistency and minimize scoring times and retest rates, thereby contributing to the company's sales
